AttoDx's business model involves collaboration between our in-house development team, academic researchers from universities and non-profit institutes, and executives and management from for-profit companies.
James Davie – Founder, President, Chief Executive Officer James Davie founded AttoDx in 2010 as a start-up technology company. He has been involved in the development of start-ups for over 30 years in the medical device, biotech, and pharmaceutical industries, as well having as a background in basic research. Companies he has worked with includes Blood Cell Storage Inc (BCSI), Aptein (acquired by Cambridge Antibody Technology), ZymoGenetics, and Centocor. His career has spanned a range of positions including founder, president, and business manager with responsibilities for strategic planning, scientific team development, business development, operations, fund-raising, and financial analysis. He holds a B.A. in Biochemistry from Pomona College,and a Masters in Industrial Administration from Carnegie Mellon University. He served for 18 years as a Trustee of Seattle Biomedical Research Institute and is a former board member for the Washington Biotechnology and Biomedical Association.
Paul C. Harris, PhD – Vice President, Product Development Dr. Harris began his career at Beckman Instruments (Brea,CA) as a Senior Research Immunologist and, following Beckman’s acquisition by SmithKline, as Principal Research Scientist and Project Manager, working on a variety of diagnostic products. In 1985,Paul moved to Genetic Systems (now BioRad) to develop a fully-automated, high-throughput instrument for HIV and Hepatitis testing, first as Project Manager and then as Director of Systems Development and Technical Services. From 1993 to 1995 Paul was the Director of Engineering and Manufacturing Operations at MicroProbe Corporation where he was responsible for the engineering of automated systems for diagnostic products based on DNA hybridization probe technology. From 1995 to 1997 he was Director of Research and Development for STC Technologies (now Orasure Technologies), and from 1997to 1998 he was Vice President, Systems Engineering for CellPro Incorporated. From 1998 to 2011, Paulwas Vice President of R&D and Chief Science Officer for Response Biomedical Corporation where he was responsible for all aspects of R&D for point-of-care immunodiagnostic systems, including automated instruments, software, assay development and disposables. The unifying theme in all of these positionshas been Dr. Harris’ ability to develop products that meet exacting regulatory (FDA, CE, ISO), performance, and cost requirements. Paul holds a B.S in Biology from the University of California, Irvine, and a Ph.D. in Molecular Biology and Biochemistry; Immunology, also from the University of California, Irvine. He has 20 issued US patents.
Jerry Cangelosi, PhD – Consulting Scientific Director Dr. Cangelosi is an Affiliate Member, Seattle Biomedical Research Institute, and an Affiliate Associate Professor in Epidemiology and in Global Heath, University of Washington. He has worked as a scientific consultant for AttoDx, and various international diagnostic and pharmaceutical companies. He has 18years of experience in infectious disease diagnostics development,epidemiology, and research. His work in the public and private sectors has generated 7 patents and over 60 publications in relevant fields including molecular diagnosis and molecular epidemiology. Much of this work has been technology-driven and has spanned diverse phylogenetic and biomedical systems including tuberculosis, non-tuberculous mycobacteria, waterborne pathogens, oral microbiology, and urogenital pathogens. At MicroProbe Corporation, he was involved in two successful diagnostic product launches. More recently, his laboratory at the Seattle Biomedical Research Institute developed a novel bacterial detection technology that was licensed to AttoDx. He holds a B.S. in Microbiology and Public Health from Michigan State University, and a Ph.D. in Microbiology from University of California, Davis. On October 1, 2012, Dr. Cangelosi will assume a new position as Professor, Department of Environmental and Occupational Health Sciences,University of Washington.
Scott Meschke, PhD – Consulting Scientist Dr. Meschke, Ph.D., M.S. and J.D. is an environmental and occupational health microbiologist specializing in the fate, transport, detection, and control of pathogens in environmental media (air, water, food, and surfaces.) Dr. Meschke is a member of several professional organizations including the American Society for Microbiology, International Water Association, American Water Works Association, International Association for Food Protection, International Society of Exposure Science. He is an associate professor of environmental and occupational health sciences and an adjunct associate professor of civil and environmental engineering and the University of Washington. Some of his research interest are development of methods for detection of viruses and bacteria in water and food, environmental surveillance for viruses, market prevalence for food- borne pathogens, microbiological quality of produce, irrigation and produce wash water quality, quantitative microbial risks assessment (QMRA), infection control, indicators of fecal contamination, survival and persistence of pathogenic microorganisms. Dr. Meschke holds a Ph.D. in microbiology from the University of North Carolina, M.S. in environmental science from Indiana University, and a J.D. from the University of Kansas.
Harvey Hoyt, MD – Consulting Medical Director Dr. Hoyt has extensive knowledge of the Biotechnology and Diagnostics industries, based on decades of experience with multi-national corporations and startups including thirteen years at Baxter International (Vice President, Baxter DX Group), and followed years at other medical diagnostics and supply companies. In the pharmaceutical industry, Dr Hoyt has managed (therapeutics, in-vitro diagnostics, and biologics) in R&D, technical development, business development, and general management at the COO and CEO levels. He has taken two companies public as CEO, had P&L responsibilities, formulated strategic and operational business plans,developed organizations, partnered with industries and universities, licensed products in and out, and raised investments for start-ups having been involved in over $250 million of private and public equity funding. Dr. Hoyt has played key roles in gaining FDA approval of eighty 510(k) and nineteen new drug applications and product marketing applications. These products have annual sales exceeding $7 billion. Dr. Hoyt received his M.D. from Washington University St. Louis, Missouri.
Business Advisory Board
Charles “Chuck”Grindstaff- Mr. Grindstaff is Chief Executive Officer for Siemens PLM Software, a business unit of the Siemens Industry Automation Division. He first joined the company in 1978, when it was known as Unigraphics Solutions, and he held a variety of R&D positions during his first decade with the organization. Chuck subsequently left the company to serve as president and CEO of Waveframe Corporation, which developed and manufactured digital signal processing systems for high-end motion picture applications. He was awarded a Scientific and Engineering Award from the Motion Picture Academy of the Arts and Sciences for this ground breaking work and its long-term impact on the industry. Upon his return to Unigraphics in 1994, Chuck took over leadership of the product business unit and, in 2000, assumed a broader role as vice president of Unigraphics products and operations. In 2001, Unigraphics merged with Structural Dynamics Research Corporation to form UGS, which Siemens acquired and re-branded as Siemens PLM Software in 2007. In October 2010, Mr. Grindstaff was appointed president, while also retaining his position as Chief Technology Officer. In October 2011, he assumed the role of CEO. Chuck received a B.A in biochemistry from Pomona College in Claremont, California.
Mark Legaz, Ph.D.
-Dr. Mark Legaz is the President and CEO of Intersect Systems, Inc., a medical diagnostic products company, and is the Founder and Consultant to Catch, Inc, of Seattle, Washington, whose diagnostic technologies were acquired by Axis-Shield of Scotland. Dr. Legaz is a research biochemist with over 40 years of academic and corporate experience. He has developed and obtained FDA clearance for over 20 reagent formulations utilizing acombination of mammalian and microbial enzymes. Products developed by Dr. Legaz’s ventures,are sold by Bayer, Olympus, Beckman, Roche, Genzyme, Medical AnalysisSystems, Johnson and Johnson, Techniconand Carolina Liquid Chemistries. Dr. Legaz has numerous peer-reviewed publications. He received a B.A. inchemistry from the University of San Diego, California; a Ph.D. in biochemistry from the University of Washington in Seattle; and did his post doctorial research in clinical chemistry at the University of Washington.